NovoCure Limited (NVCR) CEO Asaf Danziger Sells 35,500 Shares

NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 35,500 shares of the stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $22.01, for a total transaction of $781,355.00. Following the transaction, the chief executive officer now directly owns 776,862 shares of the company’s stock, valued at approximately $17,098,732.62. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Asaf Danziger also recently made the following trade(s):

  • On Thursday, September 14th, Asaf Danziger sold 37,272 shares of NovoCure Limited stock. The shares were sold at an average price of $22.01, for a total transaction of $820,356.72.
  • On Tuesday, July 11th, Asaf Danziger sold 7,383 shares of NovoCure Limited stock. The shares were sold at an average price of $19.95, for a total transaction of $147,290.85.
  • On Monday, July 10th, Asaf Danziger sold 274,359 shares of NovoCure Limited stock. The shares were sold at an average price of $18.07, for a total transaction of $4,957,667.13.
  • On Wednesday, July 5th, Asaf Danziger sold 155,088 shares of NovoCure Limited stock. The shares were sold at an average price of $18.14, for a total transaction of $2,813,296.32.
  • On Thursday, July 6th, Asaf Danziger sold 160,138 shares of NovoCure Limited stock. The shares were sold at an average price of $18.14, for a total transaction of $2,904,903.32.
  • On Monday, June 19th, Asaf Danziger sold 124,720 shares of NovoCure Limited stock. The shares were sold at an average price of $15.51, for a total transaction of $1,934,407.20.

NovoCure Limited (NVCR) traded down 4.40% during mid-day trading on Friday, reaching $20.65. 1,138,966 shares of the company were exchanged. The company has a 50 day moving average of $19.67 and a 200-day moving average of $14.42. NovoCure Limited has a 1-year low of $5.95 and a 1-year high of $22.30. The company’s market capitalization is $1.84 billion.

NovoCure Limited (NASDAQ:NVCR) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). The business had revenue of $38.38 million for the quarter, compared to analyst estimates of $42.20 million. NovoCure Limited had a negative return on equity of 69.48% and a negative net margin of 75.91%. On average, equities research analysts forecast that NovoCure Limited will post ($0.77) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “NovoCure Limited (NVCR) CEO Asaf Danziger Sells 35,500 Shares” was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://transcriptdaily.com/2017/09/16/novocure-limited-nvcr-ceo-asaf-danziger-sells-35500-shares.html.

Several research analysts have commented on NVCR shares. Zacks Investment Research raised shares of NovoCure Limited from a “sell” rating to a “buy” rating and set a $19.00 price objective for the company in a report on Thursday, June 29th. Mizuho began coverage on shares of NovoCure Limited in a report on Wednesday, September 6th. They set a “buy” rating and a $25.00 price objective for the company. BidaskClub downgraded shares of NovoCure Limited from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Deutsche Bank AG reaffirmed a “hold” rating and issued a $19.00 price target (up previously from $18.00) on shares of NovoCure Limited in a report on Monday, July 17th. Finally, ValuEngine raised shares of NovoCure Limited from a “sell” rating to a “hold” rating in a report on Saturday, June 3rd. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $20.00.

A number of large investors have recently bought and sold shares of the business. California State Teachers Retirement System boosted its holdings in NovoCure Limited by 2.6% in the 2nd quarter. California State Teachers Retirement System now owns 102,309 shares of the medical equipment provider’s stock valued at $1,770,000 after purchasing an additional 2,600 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in NovoCure Limited by 7.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 46,116 shares of the medical equipment provider’s stock valued at $797,000 after purchasing an additional 3,266 shares during the last quarter. PointState Capital LP acquired a new position in NovoCure Limited in the 2nd quarter valued at about $5,744,000. State Street Corp boosted its holdings in NovoCure Limited by 17.0% in the 2nd quarter. State Street Corp now owns 1,082,589 shares of the medical equipment provider’s stock valued at $18,728,000 after purchasing an additional 157,642 shares during the last quarter. Finally, Gotham Asset Management LLC acquired a new position in NovoCure Limited in the 2nd quarter valued at about $534,000. Institutional investors own 36.84% of the company’s stock.

About NovoCure Limited

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply